Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.

News Market Reaction – AVTX

+1.58%

1 alert

+1.58% News Effect

On the day this news was published, AVTX gained 1.58%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Cantor Global Healthcare Conference
Fireside Chat
September 3, 2025, at 2:10 pm ET

H.C.Wainwright 27th Annual Global Investment Conference
Presentation
September 9, 2025, at 2:30 pm ET

Stifel 2025 Virtual Immunology and Inflammation Forum
Fireside Chat
September 15, 2025, at 11:00 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.¹ It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune mediated inflammatory diseases.^1-3

References: ¹Dinarello CA. Immunol Rev. 2018;281(1):8-27. ²Kany S et al. Int J Mol Sci. 2019;20(23):6008. ³Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com 
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

FAQ

When is Avalo Therapeutics (AVTX) presenting at the Cantor Global Healthcare Conference 2025?

Avalo Therapeutics will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 pm ET.

What type of company is Avalo Therapeutics (AVTX)?

Avalo Therapeutics is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases.

Where can investors watch Avalo Therapeutics' (AVTX) conference presentations?

Investors can access live webcasts and replays of the presentations under the 'News / Events' section of Avalo Therapeutics' investor relations website at https://ir.avalotx.com. Replays will be available for at least 30 days.

Which investor conferences will Avalo Therapeutics (AVTX) attend in September 2025?

Avalo will attend three conferences: the Cantor Global Healthcare Conference (Sept 3), H.C. Wainwright Global Investment Conference (Sept 9), and Stifel Virtual Immunology and Inflammation Forum (Sept 15).